drugset / Trial / NCT03278522

Ramosetron Pre-treatment for PONV and QT Prolongation

NCT03278522

Phase 4 Completed 64 enrolled Konkuk University Medical Center
RandomizedParallel-groupTriple-blindPrevention

Summary

Ramosetron is commonly used to prevent postoperative nausea and vomiting (PONV) in the Eastern Asia. The prolongation of QTc interval is a main side effect. In this study, the pre-treatment time of ramosetron to decrease PONV, and QTc prolongation is compared.

Timeline

Start
2017-07-01
Primary completion
2018-02-28
Completion
2018-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ramosetron Small molecule 0.6 mg Intravenous

Indications

No indication recorded.